Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758430 · ClinicalTrials.gov registry record
A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 28
- Enrollment target
NCT03758430: Completed study, sponsored by Eli Lilly and Company.
NCT03758430 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03758430 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given. The study will last about 18 weeks.
Primary Outcome
Change from Baseline to Week 16 in HbA1c
Interventions
- OTHER Meal-Tagging App
- DEVICE Fitness Tracker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2020-08-07 |
What the finished NCT03758430 record still lists
NCT03758430 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Meal-Tagging App is the first listed.
NCT03758430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03758430 about?
NCT03758430 is a clinical study titled "A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes". The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given. The study will last about 18 weeks.
What is the current status of trial NCT03758430?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-02-06. Estimated completion is 2020-08-07.
What interventions are being tested in trial NCT03758430?
The interventions under investigation include: Meal-Tagging App (OTHER), Fitness Tracker (DEVICE).
Who is sponsoring clinical trial NCT03758430?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI